MBX · Nasdaq · CIK 0001776111

MBX Biosciences, Inc.

MBX Biosciences, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 22, 2026. Its EDGAR record lists 24 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$87.0M
Form 4 filings on record, past 12 months
24

Company overview

Legal name (as filed)
MBX Biosciences, Inc.
Ticker
MBX
SEC Central Index Key (CIK)
0001776111
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
CARMEL, IN
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
<br>Emerging growth company
Position in SEC ticker list
#1834 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from MBX Biosciences, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2023n/aFY2024n/aFY2025
Net income
-$32.6MFY2023-$61.9MFY2024-$87.0MFY2025
MBX annual results
ItemFY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue———
Net income-$32.6M-$61.9M-$87.0M
Diluted EPS-$31.96-$5.82-$2.38
Total assets$84.2M$268.5M$385.1M
Cash and equivalents$30.5M$49.4M$75.3M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

MBX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 12, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 22, 20268-KDirector or officer change· period Oct 20, 2026Document · Index
Apr 22, 2026DEF 14ADefinitive proxy statement· period Apr 22, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about MBX Biosciences, Inc., by form type:

4 ×14144 ×98-K ×7SCHEDULE 13G/A ×3SCHEDULE 13D/A ×2SCHEDULE 13G ×23 ×110-Q ×1DEFA14A ×1
MBX recent filings
FiledFormWhat it isOriginal
Oct 22, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 20, 2026Document · Index
Oct 22, 20263Initial statement of beneficial ownership· period Oct 20, 2026Document · Index
Oct 22, 20268-KDirector or officer change· period Oct 20, 2026Document · Index
Aug 27, 20268-KRegulation FD disclosure; Other events· period Aug 27, 2026Document · Index
Aug 17, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 10, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Aug 10, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 20268-KResults of operations; Regulation FD disclosure; Other events· period Aug 6, 2026Document · Index
Aug 5, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 4, 2026Document · Index
Aug 4, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 4, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 4, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 3, 2026Document · Index
Aug 4, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 3, 2026Document · Index
Jul 29, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 13, 20268-KDirector or officer change· period Jul 9, 2026Document · Index
Jul 8, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 8, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jun 24, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jun 12, 20268-KRegulation FD disclosure; Other events· period Jun 12, 2026Document · Index
Jun 10, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 9, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 5, 20268-KDirector or officer change; Shareholder vote results· period Jun 4, 2026Document · Index
May 13, 2026144Notice of proposed sale of securitiesDocument · Index
May 11, 2026144Notice of proposed sale of securitiesDocument · Index
May 11, 20264Statement of changes in beneficial ownership (insider trade)· period May 8, 2026Document · Index
May 11, 20268-KRegulation FD disclosure; Other events· period May 11, 2026Document · Index
May 8, 2026144Notice of proposed sale of securitiesDocument · Index
May 8, 2026144Notice of proposed sale of securitiesDocument · Index
May 8, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
May 8, 20264Statement of changes in beneficial ownership (insider trade)· period May 6, 2026Document · Index
May 8, 20264Statement of changes in beneficial ownership (insider trade)· period May 6, 2026Document · Index

Insider filing activity

24 Form 4 filings appear in MBX Biosciences, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Indiana

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001776111 and XBRL company facts. MBX Biosciences, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.